2.65
-0.04 (-1.49%)
| Previous Close | 2.69 |
| Open | 2.63 |
| Volume | 618,882 |
| Avg. Volume (3M) | 303,278 |
| Market Cap | 71,471,032 |
| Price / Book | 0.360 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.50 |
| Total Debt/Equity (MRQ) | 11.19% |
| Current Ratio (MRQ) | 16.92 |
| Operating Cash Flow (TTM) | -47.42 M |
| Levered Free Cash Flow (TTM) | -32.29 M |
| Return on Assets (TTM) | -32.46% |
| Return on Equity (TTM) | -55.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Mixed |
| Biotechnology (Global) | Bearish | Mixed | |
| Stock | Alto Neuroscience, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -1.00 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.48% |
| % Held by Institutions | 89.38% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alpha Wave Global, Lp | 31 Dec 2024 | 3,707,757 |
| Vestal Point Capital, Lp | 31 Dec 2024 | 915,000 |
| 72 Investment Holdings, Llc | 31 Dec 2024 | 667,778 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Mar 2025 | Announcement | Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights |
| 13 Mar 2025 | Announcement | Christopher Nixon Cox Named Chairman of High-Trend International Group |
| 25 Feb 2025 | Announcement | Alto Neuroscience to Participate in Upcoming Investor Conferences |
| 19 Feb 2025 | Announcement | Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker |
| 12 Feb 2025 | Announcement | Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |